AbbVie secures positive EU panel backing to expand Maviret to acute Hepatitis C
Share
AbbVie (NYSE:ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection.
